221 related articles for article (PubMed ID: 27861184)
21. Catecholaminergic polymorphic ventricular tachycardia in children: analysis of therapeutic strategies and outcomes from an international multicenter registry.
Roston TM; Vinocur JM; Maginot KR; Mohammed S; Salerno JC; Etheridge SP; Cohen M; Hamilton RM; Pflaumer A; Kanter RJ; Potts JE; LaPage MJ; Collins KK; Gebauer RA; Temple JD; Batra AS; Erickson C; Miszczak-Knecht M; Kubuš P; Bar-Cohen Y; Kantoch M; Thomas VC; Hessling G; Anderson C; Young ML; Cabrera Ortega M; Lau YR; Johnsrude CL; Fournier A; Kannankeril PJ; Sanatani S
Circ Arrhythm Electrophysiol; 2015 Jun; 8(3):633-42. PubMed ID: 25713214
[TBL] [Abstract][Full Text] [Related]
22. Current management of inherited arrhythmia syndromes associated with the cardiac ryanodine receptor.
Przybylski R; Abrams DJ
Curr Opin Cardiol; 2023 Jul; 38(4):390-395. PubMed ID: 37016946
[TBL] [Abstract][Full Text] [Related]
23. In silico prediction of drug therapy in catecholaminergic polymorphic ventricular tachycardia.
Yang PC; Moreno JD; Miyake CY; Vaughn-Behrens SB; Jeng MT; Grandi E; Wehrens XH; Noskov SY; Clancy CE
J Physiol; 2016 Feb; 594(3):567-93. PubMed ID: 26515697
[TBL] [Abstract][Full Text] [Related]
24. Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia.
Davidson R; Medeiros M
J Med Life; 2023 Aug; 16(8):1294-1296. PubMed ID: 38024821
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic approach for patients with catecholaminergic polymorphic ventricular tachycardia: state of the art and future developments.
van der Werf C; Zwinderman AH; Wilde AA
Europace; 2012 Feb; 14(2):175-83. PubMed ID: 21893508
[TBL] [Abstract][Full Text] [Related]
26. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
27. Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans.
Watanabe H; Chopra N; Laver D; Hwang HS; Davies SS; Roach DE; Duff HJ; Roden DM; Wilde AA; Knollmann BC
Nat Med; 2009 Apr; 15(4):380-3. PubMed ID: 19330009
[TBL] [Abstract][Full Text] [Related]
28. Effects of flecainide therapy on inappropriate shocks and arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Jacquemart C; Ould Abderrahmane F; Massin MM
J Electrocardiol; 2012; 45(6):736-8. PubMed ID: 22672791
[TBL] [Abstract][Full Text] [Related]
29. A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.
Claudio B; Alice M; Daniel S
Mini Rev Med Chem; 2018; 18(6):476-482. PubMed ID: 28685702
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of ivabradine to control ventricular arrhythmias in catecholaminergic polymorphic ventricular tachycardia.
Vaksmann G; Klug D
Pacing Clin Electrophysiol; 2018 Oct; 41(10):1378-1380. PubMed ID: 29989676
[TBL] [Abstract][Full Text] [Related]
31. Implantable cardioverter-defibrillator use in catecholaminergic polymorphic ventricular tachycardia: A systematic review.
Roston TM; Jones K; Hawkins NM; Bos JM; Schwartz PJ; Perry F; Ackerman MJ; Laksman ZWM; Kaul P; Lieve KVV; Atallah J; Krahn AD; Sanatani S
Heart Rhythm; 2018 Dec; 15(12):1791-1799. PubMed ID: 30063211
[TBL] [Abstract][Full Text] [Related]
32. Catecholaminergic Polymorphic Ventricular Tachycardia: Clinical Characteristics, Diagnostic Evaluation and Therapeutic Strategies.
Aggarwal A; Stolear A; Alam MM; Vardhan S; Dulgher M; Jang SJ; Zarich SW
J Clin Med; 2024 Mar; 13(6):. PubMed ID: 38542006
[TBL] [Abstract][Full Text] [Related]
33. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
Miyata K; Ohno S; Itoh H; Horie M
Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
[TBL] [Abstract][Full Text] [Related]
34. Ventricular arrhythmia suppression with ivabradine in a patient with catecholaminergic polymorphic ventricular tachycardia refractory to nadolol, flecainide, and sympathectomy.
Kohli U; Aziz Z; Beaser AD; Nayak HM
Pacing Clin Electrophysiol; 2020 May; 43(5):527-533. PubMed ID: 32259298
[TBL] [Abstract][Full Text] [Related]
35. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
[TBL] [Abstract][Full Text] [Related]
36. Flecainide Is Associated With a Lower Incidence of Arrhythmic Events in a Large Cohort of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia.
Bergeman AT; Lieve KVV; Kallas D; Bos JM; Rosés I Noguer F; Denjoy I; Zorio E; Kammeraad JAE; Peltenburg PJ; Tobert K; Aiba T; Atallah J; Drago F; Batra AS; Brugada R; Borggrefe M; Clur SB; Cox MGPJ; Davis A; Dhillon S; Etheridge SP; Fischbach P; Franciosi S; Haugaa K; Horie M; Johnsrude C; Kane AM; Krause U; Kwok SY; LaPage MJ; Ohno S; Probst V; Roberts JD; Robyns T; Sacher F; Semsarian C; Skinner JR; Swan H; Tavacova T; Tisma-Dupanovic S; Tfelt-Hansen J; Yap SC; Kannankeril PJ; Leenhardt A; Till J; Sanatani S; Tanck MWT; Ackerman MJ; Wilde AAM; van der Werf C
Circulation; 2023 Dec; 148(25):2029-2037. PubMed ID: 37886885
[TBL] [Abstract][Full Text] [Related]
37. Catecholaminergic polymorphic ventricular tachycardia: important messages from case reports.
van der Werf C; Wilde AA
Europace; 2011 Jan; 13(1):11-3. PubMed ID: 20851823
[No Abstract] [Full Text] [Related]
38. A human pluripotent stem cell model of catecholaminergic polymorphic ventricular tachycardia recapitulates patient-specific drug responses.
Preininger MK; Jha R; Maxwell JT; Wu Q; Singh M; Wang B; Dalal A; Mceachin ZT; Rossoll W; Hales CM; Fischbach PS; Wagner MB; Xu C
Dis Model Mech; 2016 Sep; 9(9):927-39. PubMed ID: 27491078
[TBL] [Abstract][Full Text] [Related]
39. Catecholaminergic polymorphic ventricular tachycardia.
Leenhardt A; Denjoy I; Guicheney P
Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):1044-52. PubMed ID: 23022705
[No Abstract] [Full Text] [Related]
40. Precision medicine in catecholaminergic polymorphic ventricular tachycardia: Recent advances toward personalized care.
Siu A; Tandanu E; Ma B; Osas EE; Liu H; Liu T; Chou OHI; Huang H; Tse G
Ann Pediatr Cardiol; 2023; 16(6):431-446. PubMed ID: 38817258
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
